| LRRK2+/PD- | LRRK2+/PD+ | LRRK2-/PD+ | LRRK2-/PD- |
p valuea
|
---|
Gender M(F) | 11(15) | 3(12) | 5(6) | 0(3) | ns |
Age | 62.5 (56-67.25) | 58 (53-69) | 57 (50-64) | 73 (60-75) | ns |
Age at onset | NA | 55 (47-65) | 57 (50-60) | NA | ns |
LEDD | NA | 600 (375-662.5) | 400 (300-600) | NA | ns |
UPDRS_III | 4.5 (0-6) | 18 (15-20) | 18 (16-22.5) | 0 (0-0) | <0.0001 |
MoCA | 26 (26-28) | 26 (25-27) | 27 (26-28) | 26 (<26-30) | 0.01 |
H&Y | 0 (0-0) | 2 (2-2.5) | 2 (2-2) | 0 (0-0) | <0.0001 |
-
LEDD is L-dopa equivalent daily dosage, UPDRS is Unified Parkinson’s Disease Rating Scale, MoCA is Montreal Cognitive Assessment, H&Y is Hoehn & Yahr scale, NA is not applicable; Values reported are group median (interquartile range). aDetermined by comparing LRRK2+/PD- to LRRK2+/PD+ using the Dunn post hoc test following Kruskal-Wallis test of all groups. ns is not significant as determined by Pearson chi square (gender), ANOVA (age at test), t test (age at onset), Mann-Whitney test (LEDD) and Kruskal-Wallis test (H&Y, UPDRS III)